This transcript has been edited for clarity.
Robert A. Harrington, MD: Hi. This is Bob Harrington from Stanford University, here on theheart.org | Medscape Cardiology. Over the past several years, I've had the pleasure of doing a yearly wrap-up in December with my good friend and colleague, Dr Mike Gibson, from Boston.
In these segments, what we'd like to do is cover the landscape of cardiology. What are some of the trends? What are some of the things that Mike and I are talking about with our broader circle of colleagues that really caught our attention in the past year?
This year, I thought we'd cover topics that will run the gamut from what I'll call high-level policy issues to some specific clinical trial observations. Mike and I will, in our usual way, go back and forth.
With that, let me introduce my good friend and colleague. Dr Mike Gibson is an interventional cardiologist at Beth Israel Deaconess in Boston. He's also a professor of medicine at the Harvard Medical School, and he is the CEO of the Baim Institute, a not-for-profit academic research organization. Mike, thanks for joining us here on theheart.org.
C. Michael Gibson, MD: It must be December.
